Supernus Pharmaceuticals Inc (Supernus Pharmaceuticals) develops and commercializes products for the treatment of central nervous system diseases. Its marketed products include Qelbree, GOCOVRI, Oxtellar XR, APOKYN, Trokendi XR, XADAGO, MYOBLOC, ONAPGOTM. Qelbree is a non-stimulant for treating attention-deficit hyperactivity disorder (ADHD) in adults and children 6 years and older. GOCOVRI treats dyskinesia and "OFF" episodes in Parkinson's Disease patients on levodopa therapy. Oxtellar XR is an extended-release treatment for partial-onset seizures in patients 6 years and older. APOKYN is used for acute treatment of "OFF" episodes in advanced Parkinson's Disease. Trokendi XR treats epilepsy and prevents migraines in patients 6 years and older. XADAGO is an adjunctive treatment for "OFF" episodes in Parkinson's Disease. MYOBLOC treats cervical dystonia and chronic sialorrhea in adults. ONAPGO is a subcutaneous infusion for motor fluctuations in advanced Parkinson's Disease. The company harnesses its proprietary technology to advance its market and pipeline products. The technology platforms of Supernus include Microtrol, Solutrol, and EnSoTrol (osmotic delivery system). These technologies enable the company to develop drugs with greater efficacy, improved tolerability, and enhanced patient compliance in certain specific applications. The company employs the Microtrol technology platform for filling the capsules or compressing formulation into tablets with either coated or uncoated multi-particulates for achieving custom release profiles. Solutrol is a matrix delivery system that delivers poorly soluble, pH-dependent, and highly soluble compounds in a complete and reproducible manner. EnSoTrol is an osmotic delivery system that consists of solubility-enabled agents (core and other) surrounded by a semi-permeable membrane, which has a laser-drilled hole. This technology facilitates constant release.

Supernus Pharmaceuticals is committed to the development of innovative product candidates in neurology and psychiatry. The company is actively engaged in R&D efforts, focusing on a pipeline of novel CNS product candidates for the treatment of various CNS conditions. Significant resources are devoted to these activities, with expectations of incurring substantial expenses as product candidates are developed through FDA approval or until program termination. The company is also working on expanding product indications for approved products and enhancing its intellectual property portfolio. Supernus Pharmaceuticals' R&D unit is responsible for managing the company's research and development activities, including the development of novel CNS product candidates and the expansion of product indications for approved products. The company has multiple patents covering its commercial products and product candidates, including Trokendi XR, Oxtellar XR, Qelbree, GOCOVRI, Osmolex ER, XADAGO, and ZURZUVAE. The pipeline products include SPN-817, SPN-820, SPN-443, and zuranolone. Supernus Pharmaceuticals has technology alliances, such as the development agreement with Navitor Pharmaceuticals Inc for NV-5138. In FY2025, the company incurred as expense of US$106.2 million on R&D, which as a percentage of revenue, stood at 14.7%.